More on VRX
Data
Financials
Upcoming Events
News
Click line-items for a historical chart and %
| Net income | 68.27M |
| Income from discontinued operations | -432K |
| Depreciation and amortization | 51.4M |
| Provision for losses on accounts receivable and inventory | 191K |
| Stock compensation expense | 11.75M |
| Excess tax deduction from stock options exercised | -3.24M |
| Translation and exchange (gains) losses, net | 774K |
| Impairment charges and other non-cash items | 5.04M |
| Payments of accreted interest on long-term debt | 0 |
| Deferred income taxes | 13.04M |
| Gain on extinguishment of debt | 0 |
| Accounts receivable | 3.71M |
| Inventories | -10.21M |
| Prepaid expenses and other assets | 3.55M |
| Trade payables and accrued liabilities | -13.28M |
| Income taxes | 5.51M |
| Other liabilities | -8M |
| Cash flow from operating activities in continuing operations | 128.07M |
| Cash flow from operating activities in discontinued operations | -11K |
| Net cash provided by operating activities | 128.06M |
| Capital expenditures | -8.54M |
| Proceeds from sale of assets | 417K |
| Proceeds from sale of businesses | 0 |
| Proceeds from investments | 13.59M |
| Purchase of investments | 0 |
| Loans and advances (to) from joint ventures | -628K |
| Acquisition of businesses, license rights and product lines | -466.84M |
| Cash flow from investing activities in continuing operations | -462M |
| Cash flow from investing activities in discontinued operations | 801K |
| Net cash used in investing activities | -461.2M |
| Payments on long-term debt and notes payable | -8.86M |
| Proceeds from issuance of long-term debt and notes payable | 427.82M |
| Stock option exercises and employee stock purchases | 26.85M |
| Payments of employee withholding taxes related to equity awards | -1.3M |
| Excess tax deduction from stock options exercised | 3.24M |
| Purchase of treasury stock | -106.59M |
| Cash flow from financing activities in continuing operations | 341.16M |
| Cash flow from financing activities in discontinued operations | 0 |
| Net cash provided by financing activities | 341.16M |
| Effect of exchange rate changes on cash and cash equivalents | -712K |
| Net increase in cash and cash equivalents | 7.3M |
| Cash and cash equivalents at beginning of period | 68.08M |
| Cash and cash equivalents at end of period | 75.38M |
Entities mentioned with VRX
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Pershing Square Capital | View Related Stories »
- William Ackman | View Related Stories »
- FDA | View Related Stories »
- Pre Market Movers | View Related Stories »
- Morgan Stanley | View Related Stories »
- Standard & Poor's | View Related Stories »
- Show More...
